Evidence map›Paper›PMID 28629333›Full record

ArticleBMC infectious diseases2017

Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.

Mengqiu Gao, Jingtao Gao, Jian Du, Yuhong Liu, Yao Zhang, Liping Ma, Fengling Mi, Liang Li, Shenjie Tang, Trial Team

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02901288 (Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02901288 phase4unknown statusnot on this map

Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial

TypeinterventionalSponsorBeijing Chest HospitalRan2016 to 2018Enrolled3,900ConditionsTuberculosis, PulmonaryArmsIsoniazid, Rifampicin, Pyrazinamide, Ethambutol, Levofloxacin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mengqiu GaoBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Jingtao GaoBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Jian DuBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Yuhong LiuBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Yao ZhangFamily Health International 360 (FHI360), Beijing, 100020, China.
Liping MaBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Fengling MiBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China.
Liang LiBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China. liliang@tb123.org.
Shenjie TangBeijing Chest Hospital, Capital Medical University, Tuberculosis and Thoracic Tumor Research Institute, Beijing101149, Beijing, China. tangsj1106@hotmail.com.
Trial Team
Capital Medical University · CNBeijing Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShortening the standard 6-month treatment for drug-susceptible pulmonary tuberculosis (DS-PTB) would be a major improvement for TB case management and disease control.

methodsWe are conducting a randomized, open-label, controlled, non-inferiority trial involving patients with smear-positive, newly diagnosed DS-PTB cases nationwide to assess the efficacy and safety of two 4.5- month regimens in comparison to the standard 6-month WHO recommended regimen. The regimen used in one experiment group is a 4.5-month fluoroquinolone-containing regimen, which consists of full course of levofloxacin, isoniazid (H), rifampin (R), parazinamid (Z) and ethambutol (E). Regimen used in the second experiment group includes 4.5-month full course of H, R, Z, E with levofloxacin removed. Patients in the control group, receive H, R, Z and E for 2 months, followed by 4 months of H and R. The primary endpoint is treatment failure or relapse within 24 month after treatment completion. DISCUSSION: Results from this trial along with other studies will contribute to the science of constructing a shorter, effective and safe regiment for TB patients.

trial registrationThe protocol has been registered on ClinicalTrials.gov on 2 September,2016 with identifier NCT02901288 .

Indexed as

AdolescentAdultAgedAntitubercular AgentsDrug Therapy, CombinationEthambutolFemaleHumansIsoniazidLevofloxacinMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRifampinTreatment OutcomeAntitubercular AgentsEthambutolIsoniazidLevofloxacinRifampinClinical trialDrug susceptible pulmonary tuberculosisShort course chemotherapy

Identifiers

PMID28629333
PMCPMC5474865
OpenAlexW2626088672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.